Daphne Koller was not on this episode. A recording of them was played into it, so these
are their words but not an appearance on No Priors. It still counts as said, and it is kept out of every score on their page.
Daphne Koller, founder and CEO of insitro and machine learning pioneer, explains why purely end-to-end deep learning is insufficient for clinical applications without causal reasoning and interpretability.
“What I think we're starting to see right now is a the pendulum starting to swing back in the sense that there is a greater understanding that you really need a bit of both. You need that hugely powerful pattern recognition that we get from deep learning, but you also need the ability to reason about things like causality, and you also need some interpretability of your deep learning models so that you can potentially convey to a clinician why you made the decision that you did. And so what we're ending up with as a really powerful Paradigm is some kind of synthesis of the ideas from both of these disciplines coming together.”
quote is from the automated transcript, cleaned for reading:
filler sounds and stutters are removed, nothing is rephrased. names can be misheard
(the analysis reads context, assessments check outside sources). how →
More from Daphne Koller
Insight
Koller: AI requires synthesizing deep learning with causal and interpretable models
“What I think we're starting to see right now is a the pendulum starting to swing back in the sense that there is a greater understanding that you really need a bit of both. You need that hugely powerful pattern recognition that we get from deep learning, but y…”
Daphne KollerMay 19, 2023▶ 2:28No Priors Ep. 6 | With Daphne Koller from Insitro
Insight
Koller: Tech workers entering biotech often disrespect biological challenges and create friction
“There's a lot of tech people who come in To life sciences, and it's like, we have that cell verbal. We are the smartest. We're machine learning. We're going to solve everything. And they don't respect the challenges of the other discipline. They sometimes don'…”
Daphne KollerMay 19, 2023▶ 40:22No Priors Ep. 6 | With Daphne Koller from Insitro
Insight
Koller: Most drug failures stem from wrong target selection, not trial design
“It's a place where most programs fail is because we're just not modulating the right thing. It's the wrong target in the wrong indication or the wrong patient population.”
Daphne KollerMay 19, 2023▶ 13:14No Priors Ep. 6 | With Daphne Koller from Insitro
Disclosure
Koller: Insitro aims to replace untranslatable animal models using human cellular models
“Which ultimately what we're looking to do is to replace the sort of untranslatable animal models with something that is much more driven from human biology.”
Daphne KollerMay 19, 2023▶ 16:35No Priors Ep. 6 | With Daphne Koller from Insitro
Insight
Koller: Broad patient targeting to maximize revenue causes drug trial failures
“That is one of the big things that causes drugs to fail is that you are trying to apply it more broadly. If I'm being cynical, sometimes it's supposed to maximize the revenues that you can get from a drug versus trying to figure out exactly in which patients i…”
Daphne KollerMay 19, 2023▶ 28:23No Priors Ep. 6 | With Daphne Koller from Insitro
“And so ultimately there's only so much that you can speed up biology in certain cases because biology takes as long as it takes.”
Daphne KollerMay 19, 2023▶ 33:46No Priors Ep. 6 | With Daphne Koller from Insitro
Made with StarZero
Turn any episode into a week of clips.
This entire site, over 100 episodes transcribed, diarized, checked and made playable,
runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the
moments worth sharing, cuts them, captions them, and reframes them for every feed.
We use essential cookies to make the site work. With your permission we
also use analytics cookies (Google Analytics and Mixpanel) to understand
usage and improve StarZero. See our Cookie Policy.
